FOLD

Amicus Therapeutics, Inc.

13.39 USD
-0.01 (-0.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Amicus Therapeutics, Inc. stock is up 6.52% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.94% of the previous 16 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 10 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
08 Jan 18:42 19 Jan, 2024 12.00 CALL 281 20275
08 Jan 18:43 19 Jan, 2024 12.00 CALL 305 20275
08 Jan 18:45 19 Jan, 2024 12.00 CALL 823 20275
08 Jan 18:45 19 Jan, 2024 12.00 CALL 993 20275
08 Jan 18:45 19 Jan, 2024 12.00 CALL 185 20275
08 Jan 18:45 19 Jan, 2024 12.00 CALL 307 20275
08 Jan 19:37 19 Jan, 2024 12.00 CALL 3000 20275
08 Jan 19:37 19 Jan, 2024 12.00 CALL 2000 20275
10 Jan 19:59 19 Jan, 2024 12.00 CALL 5000 16461
10 Jan 20:00 19 Jan, 2024 12.00 CALL 1159 16461

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases.